New research from Cold Spring Harbor Laboratory's dos Santos lab shows that inhibiting the BPTF protein in mice can slow or stop the spread of ER+ breast cancer and keep tumors vulnerable to common hormone therapy. The team’s findings could someday help prevent breast cancer recurrence and lead to better patient outcomes.

The ability of CD8⁺ T cells, a type of immune cell, to rapidly proliferate inside tumors is key to the success of cancer immunotherapy. In a new study, scientists from Tokyo University of Science, Japan, have identified a set of ‘signature’ genes that can determine whether these immune cells will multiply or stall within the tumor. Their findings provide a powerful pan-immunotherapy biomarker for treatment monitoring and pave the way for next-generation immunodynamic therapies.

Researchers at the HUN-REN Biological Research Centre, Szeged, Hungary, have developed an artificial-intelligence-assisted technology capable of analyzing up to one hundred patient-derived cell samples simultaneously.

The new method, described in Nature Communications, could significantly accelerate drug development and advance the field of personalized medicine.

Researchers at the HUN-REN Biological Research Centre in Szeged, Hungary, have developed an artificial-intelligence-assisted technology capable of analyzing up to one hundred patient-derived cell samples simultaneously.

The new method, described in Nature Communications, could significantly accelerate drug development and advance the field of personalized medicine.

Dr. LU Ming's group from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences, in collaboration with researchers from Huashan Hospital of Fudan University, has now identified a key acetate source by revealing how HCC cells trigger acetate secretion by tumor-associated macrophages (TAMs) through a metabolic interaction involving lactate and the lipid peroxidation–aldehyde dehydrogenase 2 (ALDH2) pathway.

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary human T cells, addressing a key manufacturing and scalability challenge in next-generation cell therapies. The research, published October 21, 2025, in Nature Biotechnology, demonstrates how CRISPRoff and CRISPRon can reprogram a patient’s own T cells for therapeutic purposes without the cell toxicity and DNA damage associated with traditional gene editing approaches.